All In Biotech

Drug Trial Radar · NCT04277663

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Last checked: Nov 19, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

136

Actual

Start

Apr 17, 2020

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.

Conditions

  • Acral Melanoma That Has Been Removed by Surgery

Interventions

  • IBI310+IBI308Drug

    In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.

  • IBI308Drug

    In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit

  • High-dose recombinant interferon a-2BDrug

    In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival rateTime frame: up to 5 years after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing cancer hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.